Solaxa
$1.1Mtotal raised · 2 rounds on record
$365klatest round · Venture round · Apr 2024 · 2 yr ago
1-10team · employees, estimated range
2021founded
Overview
Restoring Nerve Function. Solaxa is a clinical-stage biopharmaceutical company developing life-altering solutions that reignite function lost from neurodegenerative disease and nerve damage.
Funding and backers
Total raised
$1.1M
2 rounds on record
Latest round
$365k
Venture round · Apr 2024 · 2 yr ago
Team
1-10
employees, estimated range
The money's age
Long since its last round
30 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 27
New executive Solaxa Inc. Appoints Brad Navia, MD, PhD as Chief Medical Officer · solaxa.com
Jan 6, 2025
Certified Solaxa Inc. Announces FDA Clearance of IND Application for SLX-100 · solaxa.com
Sep 25, 2024
Partnership Solaxa Inc. Collaborates with National Ataxia Foundation · solaxa.com
Sep 13, 2024
Board appointment Luis Gutierrez, Director · SEC Form D
Apr 24, 2024
Raised a round Venture round $365k · SEC Form D
Feb 11, 2021
Raised a round Venture round $729k · SEC Form D
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2024 | $365k | — | SEC Form D |
| Venture round | Feb 2021 | $729k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Solaxa Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Christian WalkerExecutive Officer, DirectorSEC Form D
Luis GutierrrezExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics.
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company.
About Elpiscience is a clinical-stage biopharmaceutical company dedicated to the development of innovative immunotherapies for oncology and…
Advancing Accessible Solutions for Complex Neurodegenerative Diseases. Protecting neurons to advance treatment for neurodegenerative…
About Us Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for a wide range of…
CND advances neurodiagnostics through skin biopsy testing, including the Syn-One Test, for neurodegenerative diseases.
People
Christian Walker
Executive Officer, Director
Luis Gutierrrez
Executive Officer, Director
Lauren Sabella
Director
Luis Gutierrez
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
SOLAXA INDEX, SOLAXA:STU Historical Prices - FT.com
SOLAXA INDEXindex chart, prices and performance, plus recent news and analysis.
Read more
Report
Solaxa Inc. Appoints Brad Navia, MD, PhD as Chief Medical Officer
Solaxa Inc. Appoints Brad Navia, MD, PhD as Chief Medical Officer Bethesda, MD; June 27, 2026 - Solaxa Inc. announces that Brad Navia, MD, PhD, has joined the company in the role of Chief Medical Officer (CMO). Dr. Navia has extensive expertise in drug de
Read more
Report
Solaxa Inc. Appoints Bill Passer, MBA, as Chief Financial Officer
Solaxa Inc. Appoints Bill Passer, MBA, as Chief Financial Officer Bethesda, MD; May 15, 2026 - Solaxa Inc. announces that Bill Passer, MBA, has joined the company in the role of Chief Financial Officer (CFO). Bill is the founder of P3 Partners with over 3
Read more
Report
美時旗下Alvogen取得Solaxa小腦萎縮症新藥授權 總金額達9500萬美元
美時宣布旗下 Alvogen 與專注罕見神經疾病的生技公益公司 Solaxa達成 SLX-100 的全球授權協議共同推動 SLX-100 用於 27B 型小腦萎縮症在全球市場的開發與商業化交易總金額達 9500 萬美元
Read more
Report
Solaxa and Alvogen enter into $95M license agreement for the development and commercialization of SLX-100
Solaxa and Alvogen enter into license agreement for the development and commercialization of SLX-100 for spinocerebellar ataxia type 27B (SCA27B) Alvogen will acquire worldwide rights for SLX-100 for SCA27B and will be responsible for the commercializatio
Read more
Report
Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B
Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B Bethesda, MD - March 28, 2025 - Solaxa Inc., a biopharmaceutical public benefit corporation focused on rare neurological conditions, has announced plans to conduct a registrationa
Read more
Report
Solaxa Announces Phase 3 Clinical Trial for Spinocerebellar Ataxia Type 27B
Solaxa Inc., a biopharmaceutical public benefit corporation focused on rare neurological conditions, has announced plans to conduct a registration ...
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Bethesda
United States
HQ
1-10 est. staff